Announcements Trials
Browse Landscape

Status

No longer available 1Available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 3Expanded_access 2

Sponsor

Cancer Type

Breast 2

Conditions

Triple Negative Breast Neoplasms 2

Interventions

3-Iodobenzylguanidine 9Amifampridine 6nilotinib 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3fludarabine phosphate 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × leronlimab × Clear all
NCT07536815 2026-04-27

An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)

CytoDyn, Inc.

Available
Breast

Triple Negative Breast Neoplasms

NCT04313075 2025-07-15

A Compassionate Use Study of Leronlimab in Breast Cancer

CytoDyn, Inc.

No longer available
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡